Showing 141 - 160 results of 313 for search 'Li Yu (author)', query time: 0.07s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149

    Genetic and Plasma Proteomic Approaches to Identify Therapeutic Targets for Graves’ Disease and Graves’ Ophthalmopathy by Ke C, Yu Y, Li J, Yu Y, Sun Y, Wang Y, Wang B, Lu Y, Tang M, Wang N, Chen Y

    Published 2025-02-01
    “…Chenxin Ke,1,* Yuefeng Yu,1,* Jiang Li,1 Yuetian Yu,1 Ying Sun,1 Yuying Wang,1 Bin Wang,1 Yingli Lu,1 Mengjun Tang,2 Ningjian Wang,1 Yi Chen1 1Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 2Orthopedic Department, Taizhou Hospital of Zhejiang Province, Zhejiang University, Taizhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yi Chen, Email chenyi9h@126.com; Ningjian Wang, Email wnj486@126.comBackground: The blood proteome is a major source of biomarkers and therapeutic targets. …”
    Get full text
    Article
  10. 150
  11. 151
  12. 152
  13. 153
  14. 154
  15. 155
  16. 156
  17. 157
  18. 158
  19. 159
  20. 160

    Simultaneous Determination of Multiple Acid-Suppressing Drugs by UPLC-MS/MS Method and Application for Pharmacokinetics Study by Li X, Liu S, Yu M, Xi W, Wu X, Liu D, Liu A, Wang H

    Published 2025-02-01
    “…Xiuqi Li,1,* Shupeng Liu,1,* Mengyang Yu,1 Wanlin Xi,1 Xiaofei Wu,1 Dan Liu,2 Aijing Liu,1 Hongyun Wang1 1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China; 2School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hongyun Wang, Email wanghy@pumch.cnBackground: Proton pump inhibitors (PPIs) and potassium competitive acid blockers (P-CABs) are widely used to treat acid-related diseases (ARDs). …”
    Get full text
    Article